French biotech SME producing lentiviral gene therapy vectors and developing treatments for lymphatic disease.
Flash Therapeutics (operating under the Vectalys brand, vectalys.com) is a Toulouse-based biotech SME specializing in lentiviral vector production and gene therapy development. Their core business is manufacturing viral gene delivery tools — the vehicles used to insert therapeutic genes into patient cells — for both industrial partners and clinical-stage programs. They began as a contract development and manufacturing organization (CDMO) for gene therapy vectors, then extended into therapeutic applications, most notably using gene therapy to restore lymphatic function in patients with lymphedema. In short, they both make the tools of gene therapy and apply those tools to specific diseases.
The LentiFactory/MAGIC project (2017) focused explicitly on industrial and clinical manufacturing of gene delivery tools, and TheraLymph (2020-2025) builds directly on that vector production capability.
TheraLymph (2020-2025, €1.13M) targets lymphedema by using gene therapy to restore lymphatic endothelial function, demonstrating therapeutic application of their platform.
TheraLymph keywords include 'endothelial,' indicating they work at the intersection of gene delivery and vascular/lymphatic endothelial cell targeting.
Their SME-1 instrument project (LentiFactory, 2017) was a feasibility study for scaling gene delivery tool manufacturing to industrial and clinical standards.
Flash Therapeutics entered H2020 as a manufacturing-focused SME: their first project (LentiFactory, 2017) was about scaling gene delivery production for industrial and clinical customers — essentially a toolmaker. By 2020, they had pivoted toward using their own tools therapeutically, joining the TheraLymph consortium to develop a gene therapy for lymphedema. The keyword record reflects this exactly: no disease-specific terms in the early period, then lymphedema, lymphatic, gene therapy, and endothelial in the recent period. The trend is a classic CDMO-to-therapeutics transition: from making tools for others to building their own therapeutic pipeline.
They are moving up the value chain from contract manufacturing into proprietary therapeutics, which suggests future collaborations will likely center on specific disease programs rather than pure vector production services.
Flash Therapeutics has both led and joined projects, though at small scale — one SME-1 phase coordinator role (a solo feasibility study) and one participant role in a larger RIA consortium. Their participation in TheraLymph alongside academic and clinical partners suggests they bring a specific technical capability (vector production) into consortia rather than driving scientific strategy. With only 10 unique partners across 2 projects, they operate in tight, specialized teams rather than broad multi-partner alliances.
Their H2020 network spans 10 unique partners across 6 countries, which is modest but consistent with highly specialized biotech SMEs that work with a focused set of academic medical centers and clinical research organizations. No dominant geographic cluster is identifiable from the available data.
Flash Therapeutics occupies a rare position in the French biotech landscape: they combine industrial-scale lentiviral vector production (a technically demanding capability that few SMEs hold) with active therapeutic development in lymphatic disease. For a consortium builder, this means they can simultaneously supply vectors and contribute disease-specific expertise — a dual role most pure-play CDMOs or pure-play therapeutics companies cannot fill. Their Toulouse base also places them in proximity to one of France's strongest biomedical research ecosystems.
